Certara said this week that it is collaborating with the Hamner Institutes for Health Sciences to explore drug-induced liver toxicity.
Under the terms of the agreement signed by both parties, the partners will integrate the Hamner's drug-induced liver injury, DILI, modeling software into Certara's Simcyp simulator and test the integrated product's simulation capabilities with respect to drug exposure and resultant liver toxicity.
Brett Howell, lead scientist and manager of the DILI-simulation initiative at the Hamner, said that the collaborators aim to develop "a computer model that helps sponsors and regulators predict which drugs will produce DILI symptoms, and which subsets of the population are most likely to be affected."